Background: The combination use of the vascular disrupting agent ombrabulin with chemotherapeutic agents was previously shown to be highly synergistic in preclinical models. Methods: In this dose-escalation study of ombrabulin (15.5-35 mg/m 2 ) in combination with doce-
Introduction
Ombrabulin (AVE8062, AC7700) is a tubulin-binding agent that targets the immature neovasculature of tumors (1, 2) . It is an analog of combretastatin, which depolymerizes microtubules thereby disorganizing the cytoskeleton (3). After i.v. infusion, ombrabulin is rapidly converted to its active metabolite, RPR258063. Ombrabulin has been shown to have high antitumor efficacy in several animal models as well as significant synergy with other anticancer agents. Ombrabulin causes vascular blood flow shutdown by attacking endothelial cells within the tumor vasculature (4) . Based on the preclinical data, the best synergistic effect was observed when ombrabulin was administered earlier than or concomitantly with other cytotoxic drugs (5) . The combination of ombrabulin with docetaxel and cisplatin was found to be highly synergistic in preclinical models, demonstrating superiority to either of the single agents alone (6) (7) (8) .
Three different schedules of ombrabulin monotherapy were previously evaluated in Caucasian patients. Ombrabulin administered once every 3 weeks was selected for its safety profile compared to other schedules (5) . Overall, 105 patients were treated with ombrabulin monotherapy at dose levels of up to 60 mg/m 2 , and the maximum tolerated dose (MTD) was established to be 50 mg/m 2 every 3 weeks (9) . Based on these overseas results, an administration regimen of every 3 weeks was chosen for Phase 1 studies in Japan. In a non-Japanese study, 69 patients were treated with escalating doses of ombrabulin (15.5- The main purpose of this study was to confirm the safety profile of ombrabulin combined with docetaxel and cisplatin in Japanese patients with advanced solid tumors.
Materials and methods

Study design
This dose escalation Phase 1 study was performed in three centers. It was designed to assess the safety, pharmacokinetics (PK) and efficacy of ombrabulin in combination with docetaxel and cisplatin administered on Day 2 in patients with advanced solid tumors. The primary objective of the study was to determine the maximum administered dose (MAD) and MTD by the incidence of DLTs during Cycle 1. If DLT was observed at first cycle in two out of three patients at each dose level, MAD was considered to be reached. In case DLT was observed at first cycle in one out of three patients, three further patients were to be included at the same dose level. If two out of six patients presented with a DLT, MAD was considered to be reached. The secondary objectives were: to assess the overall safety profile of the combination therapy; to characterize the PK profile of ombrabulin, its active metabolite RPR258063, docetaxel and cisplatin (free and total); and to evaluate the antitumor activity of the combination therapy.
The study protocol was evaluated and approved by the Institutional Review Board of each site, and all patients gave written informed consent for participation prior to conducting any study procedures. The study was performed in accordance with the Declaration of Helsinki and in accordance with the International Conference on Harmonisation guidelines on Good Clinical Practice and applicable local regulatory requirement and laws.
Patient population
To be eligible, patients had to be Japanese, aged 20-75 years old, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1, with histologically or cytologically proven advanced or recurrent solid tumors for which docetaxel-and cisplatin-based regimen was indicated, with at least 12 weeks life expectancy, adequate hematological, renal, and hepatic function, and adequate washout since prior therapy. Specific criteria for exclusion were symptomatic brain metastases and carcinomatous leptomeningitis; neuropathy and ototoxicity due to previous neurotoxic drugs; medical history of myocardial infarction, angina pectoris, congestive heart failure, coronary artery bypass graft, arrhythmia (especially severe conduction disorder, such as second or third degree atrio-ventricular block), stroke or history of arterial or venous thrombo-embolism within the past 180 days requiring anticoagulants; a baseline QTc interval of more than 450 ms or family history of long QT syndrome; growing vessel disease or ongoing wound healing process; and hypertension defined as systolic blood pressure of more than 140 mmHg or diastolic blood pressure of more than 90 mmHg, severe hypersensitivity to taxanes or polysorbate 80 or platinum compound.
Dosing and administration
Patients were treated by 30-min i.v. administered ombrabulin on Day 1 and then by 1-h i.v. docetaxel and 2-h i.v. cisplatin on Day 2. This treatment cycle was repeated every 3 weeks. All patients were adequately treated with antiemetics and hydrated according to the usual cisplatin therapeutic care of the study sites. Study treatment was continued until development of disease progression or unacceptable toxicity. Patient safety profiles and tolerability were individually assessed in Cycle 1. Dose-escalation was decided based on results of the incidence of DLTs in Cycle 1. A cycle for combined administration was defined as a 21-day period. When the next drug administration study was carried out more than 24 days after the previous administration, a cycle was regarded as delayed.
Five dose levels of ombrabulin were planned from 15. Table 1) . One cycle was defined as a 3-week period. If one of the initial three patients experienced DLT during the first cycle at the given dose level, then three additional patients were to be included at the same dose level. If no more than one out of six patients experienced a DLT, patient enrollment to the next dose level was to be performed. The same procedures were repeated until the highest dose level (Dose Level 6). If no more than one DLT (out of three or six patients) was observed at Dose Level 6, a further dose level was not to be conducted, and additional patients were to . be treated at this dose level until a total of 10 patients could be evaluated further for PK, safety and antitumoral activity. Recommended dose was defined as the highest dose level in which less than 33% of all evaluable patients experienced a DLT. As 35 mg/m 2 of ombrabulin combined with 75 mg/m 2 of docetaxel and cisplatin (Dose Level 6) was determined as the RD in Caucasian patients, this dose was set as the maximum level for Japanese patients in this study. The presence and severity of DLTs were determined in Cycle 1. DLTs included any drug-related clinical adverse events (AEs) or laboratory abnormalities. Non-vascular hematologic DLTs were defined as follows: Grade 4 neutrophils lasting more than 5 days (ANC < 0.5 × 10 9 /l); platelets <25 × 10 9 /l; hemoglobin <6.5 g/dl;
and Grade 4 with fever ≥38.0°C or Grade 3 with fever ≥38.5°C for febrile neutropenia. Non-vascular non-hematologic DLTs were defined as follows: any Grade 4 events; and Grade 3 events, except nausea with vomiting that was well controlled under antiemetic treatment, elevations in aspartate aminotransferase (AST), ALT or alkaline phosphatase (AP) lasting less than 8 days and decreasing to ≤ Grade 1 at Day 8, hypersensitivity well controlled under antihistamine and corticosteroids treatment, and diarrhea well controlled with antidiarrheic treatment. Vascular DLTs were defined as follows: clinical aspects (documented angina pectoris and myocardial infarction; and documented arterial thrombo-embolism, stroke, including transient ischemic attacks, pulmonary thrombo-embolism); hypertension (systolic BP of not less than 180 mmHg or diastolic BP of not less than 120 mmHg for at least two successive measurements taken at 30 min interval in spite of appropriate antihypertensive therapies; and acute impairment of the brain, heart and kidney); hypotension (Grade 2 or higher National Cancer Institute Common Terminology Criteria Adverse Events [NCI CTCAE] hypotension, or systolic BP of less than 90 mmHg for at least two successive measurements taken at 30 min interval while awake); cardiac markers (troponin-I value greater than the pathological limit defined by the manufacturer as a sign of myocardial necrosis); cardiac-ischemia/infarction (ST-and T-wave changes suggesting ischemia; abnormal Q-waves); cardiac left ventricular function (resting ejection fraction below 50% with more than 20% decline of resting ejection fraction from baseline value); and other vascular events (any Grade 4 events; and Grade 3 events except some AEs at tumor site, such as intratumor hemorrhage and tumor hemorrhagic necrosis that are not life-threatening).
Safety, efficacy and PK assessments
The safety population comprised all patients who had received at least one dose of study drug. The safety analysis was based on the reported AEs, DLTs, and other safety information, such as clinical examination, hematology, biochemistry, and urinalysis. Cardiovascular assessment included clinical evaluation 12-lead electrocardiogram (ECG), troponin-I or -T, creatinine phosphokinase (CPK) and fraction creatinine kinase MB (CK-MB). The safety profile was evaluated based on the incidence and severity (as graded by the NCI CTCAE v. 3.0) of AEs or laboratory abnormalities and the cumulative nature of the AEs. Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria. Patients with objective response were defined by pooling those with complete response (CR) and partial response (PR). Tumor assessment of all target or non-target lesions (measurable and non-measurable) and MRI/computed tomography (CT) were performed within 28 days of the first study drug administration. Tumor response assessments were repeated every second cycle until disease progression or treatment discontinuation. The best overall response was defined as the best tumor response observed through the study. No confirmation with two consecutive assessments was required to determine the CR or PR.
The main objectives of PK assessment were to determine the concentration of ombrabulin, its metabolite RPR258063, docetaxel and cisplatin in plasma. Plasma concentrations of ombrabulin and RPR258063 were determined by validated liquid chromatography tandem mass spectrometry (LC-MS/MS) methods, with a lower limit of quantitation (LLOQ) of 2 ng/ml. Plasma concentrations of total docetaxel were determined by an LC-MS/MS method with an LLOQ of 1 ng/ml. Plasma concentrations of total (plasma protein bound and unbound) cisplatin were determined by an ICP-MS/MS method with an LLOQ of 100 ng/ml. The PK parameters of ombrabulin, metabolite RPR258063, and cisplatin were calculated by noncompartmental analysis with validated software (PKDMS Version 2.1 with WinNonlin Professional, Version 5.2.1, Pharsight), except for maximum concentration (C max ) and time of C max (t max ), which were obtained directly from actual observations. The docetaxel PK parameters were determined using a Bayesian estimation method and the population PK model, calculated by three-compartmental analysis. 
Results
Eleven patients were treated in three investigational institutes in
Patient characteristics
All 11 patients had a PS (ECOG) of 0 or 1 at baseline. The patients consisted of three females and eight males. The median (range) of age was 66 (44-71) years. All patients had metastatic non small cell lung cancer (NSCLC) and the histology type were seven adenocarcinomas, one squamous cell carcinoma, one large cell carcinoma, one spindle cell carcinoma, and one not specified NSCLC. One patient had received prior radiotherapy or prior surgery, but no patient had received prior chemotherapy. Patient characteristics are summarized in Table 2 . 
Dose-limiting toxicities
Safety evaluation
The most common related AEs included decreased appetite (100%), constipation and alopecia (90.9%), diarrhea and fatigue (81.8%) and nausea (72.7%). Common related AEs were dysgeusia, hiccups and vomiting (54.5%), and decreased weight (45.5%). Six patients had Grade 3 or 4 AEs during treatment, including neutropenia, diarrhea, infectious enterocolitis, neutropenic infection, pneumonia, febrile neutropenia, thrombocytopenia, deep vein thrombosis, dyspnea, lymphangiosis carcinomatosa and cough (Table 3) . None of the patients experienced a fatal outcome during the study (until 30 days after the last infusion of last patient). Grade 3 or 4 hematological abnormalities were reported in eight patients during the treatment period: leukopenia (four patients), neutropenia (six patients), lymphopenia (six patients) and thrombocytopenia (one patient). Grade 3 non-hematological abnormalities such as hyponatremia (two patients) and Grade 3 hypocalcemia (one patient) were also reported.
Three patients experienced cardiac AEs that were considered related to the study treatment: Grade 1 palpitations, Grade 1 supraventricular extrasystoles and Grade 2 right ventricular failure.
PK evaluation
PK evaluation for ombrabulin, RPR258063, free/total cisplatin and docetaxel was performed at Cycle 1 on 11 patients. Note: Regardless of target or non-target lesion, the organs subjected to baseline tumor evaluation were included in this summary. The bilateral organs were regarded as single organs in tumor evaluation, e.g. left and right lungs were counted only once. short terminal elimination half-life (14.2 min). Its active metabolite, RPR258063, appeared rapidly in systemic circulation and had a longer terminal elimination half-life (~9 h) with~1.4-fold higher exposure than the parent compound (Table 4 and Fig. 1 ). No notable changes in the plasma concentrations of ombrabulin or its metabolite were observed from Cycles 2 to 4 compared to Cycle 1. After 1-h i.v. infusion of docetaxel 60 mg/m 2 , the mean ± standard deviation docetaxel clearance was 16.5 ± 3.89 l/h/m 2 (range:
11.0-24.9). The corresponding area under the curve (AUC) was 3.83 ± 0.84 μg h/ml (range: 2.44-5.44) ( Table 4 ). In all patients except one patient, C max was reached at the end of infusion for both free and total cisplatin. Total variability in the exposure of both analycfctes was low, as shown for C max (20% and 10%, respectively, for free and total cisplatin) and AUC 0-24 h (18% and 10%, respectively, for free and total cisplatin) ( Table 4 and Fig. 2 ).
Efficacy evaluation
Tumor response was assessed according to RECIST 1.1 criteria and was measured in all 11 patients. Overall, PR, stable disease (SD), and progressive disease (PD) as best overall response were observed in four patients (36.4%), four patients (36.4%), and three patients (27.3%), respectively. At Dose Level 1, three patients (60.0%) had PR, and two patients (40.0%) had SD but no PD.
Extent of exposure to study drugs
Two patients had delayed cycles due to AEs. In addition, they had the dose of ombrabulin, cisplatin and docetaxel reduced at Cycle 2. Four patients received at least four cycles, including one patient who received six cycles. The patients received a mean actual ombrabulin dose of 4.46 ± 0.67 mg/m 2 /week with a cumulative dose of 53.20 ± 23.12 mg/m 2 . Median relative dose intensity was 0.869. Overall, three patients had dose reductions because of AEs (Table 5 ). All 11 study patients discontinued the treatments. Three patients discontinued treatment because of disease progression, and three other patients stopped treatment because of AEs. Five patients discontinued the treatment due to 'other reason': four patients discontinued the study treatment after four cycles and one patient discontinued the study treatment after six cycles. Discontinuation was based on the medical practice with the docetaxel and cisplatin regimen to prevent cumulative cisplatin toxicity.
Discussion
In total, 11 Japanese patients with advanced NSCLC were examined in this study and the dose of ombrabulin could not escalate from Dose BSA, body surface area; CL, clearance; V, volume; AUC, area under the concentration-time curve; n, number of patients; SD, standard deviation; CV: coefficient of variation; Min, minimum; Max, maximum. Percentage was calculated using the number of cycles that could be reduced or delayed as the denominator. Pfizer, Astellas and MSD. Miyako Satouchi received honoraria from Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly and Taiho Pharmaceutical. Toyoaki Hida received honoraria from Novartis, Chugai Pharmaceutical and Eli Lilly. The other authors have no conflicts of interest. Sanofi K.K. provided the study drugs, collected and analyzed the data and contributed to the interpretation of the study. All authors had full access to all of the data in the study and had final responsibility for the decision to submit for publication.
